Search

Displaying results 4701 - 4710 of 10000 in total
  1. Drug

    Adecatumumab

    go.drugbank.com/drugs/DB05006
    Investigational

    Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.

  2. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment. … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.

  3. Drug

    Interferon beta-1b

    go.drugbank.com/drugs/DB00068
    ApprovedInvestigational

    Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

    Categories: Interferon Type I
  4. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR, autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor
  5. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  6. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  7. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation … , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease.

  8. Drug

    Matuzumab

    go.drugbank.com/drugs/DB05101
    Investigational

    Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

  9. Drug

    Alfimeprase

    go.drugbank.com/drugs/DB04919
    Investigational

    Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>). … It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.

  10. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.